Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, how many commercial agreements NHS England has made with manufacturers of medicines which have r resulted in indication-specific pricing between January 2020 and March 2025; and what therapeutic area these have been for.

Information provided by NHS England shows that there have been 74 commercial agreements involving indication-specific pricing arrangements between January 2020 and March 2025. The following table shows the split by therapeutic areas:

Note: therapeutic areas with fewer than five commercial agreements have been grouped under Other to avoid identification of specific commercial deals.